GPPAD - The Global Platform for the Prevention of Autoimmune Diabetes

WE RESEARCH.WE DEVELOP.

WE FIGHT.For a world without

type 1 diabetes. Supported by

Oxford

Leuven

Hannover

Munich

Dresden

Warsaw

Malmö

Hanover

GPPAD SITES IN EUROPE

GERMANY >> BAVARIALead investigator: Prof. Anette-Gabriele ZieglerHelmholtz Zentrum München,Ingolstädter Landstraße 1, 85764 NeuherbergPhone: 0800-00 00 018Email: contact@gppad.org

GPPAD Coordinating CenterPhone: 00800-33 15 33 15Email: cc@gppad.org

GERMANY >> SAXONYLead investigator: Prof. Ezio BonifacioDFG Research Center for Regenerative Therapies Dresden (CRTD)Technische Universität DresdenFetscherstraße 105, 01307 DresdenTel.: 0800-72 45 148Email: diabetesstudie.crtd@tu-dresden.de

GERMANY >> LOWER SAXONYLead investigator: Prof. Olga KordonouriKinder- und Jugendkranken-haus AUF DER BULT, Janusz – Korczak – Allee 12, 30173 HannoverPhone: 0800-37 33 37 15 Email: freder1k@hka.de

BELGIUMLead investigator: Prof. Kristina CasteelsUZ Leuven, GasthuisbergHerestraat 49, 3000 LeuvenPhone: +32-(0)-16-348554Email: freder1kstudie@uzleuven.be

POLANDLead investigator: Dr Agnieszka SzypowskaOddział Diabetologii Dziecięcej i Pediatrii Uniwersyteckie Centrum Kliniczne WUM, Dziecięcy Szpital Kliniczny im. Brud-zińskiego ul. Żwirki i Wigury 63 A, 02-091 Warszawa Phone: +48-(0)-22 317 94 44Email: kontakt@swiatbezje-dynki.pl

SWEDENLead investigator: Prof. Helena Elding LarssonClinical Research Centre, Lunds Universitet, Hus 60, plan 11 Jan Waldenströms gata 35, 214 28 MalmöPhone: +46-(0)-40-39 11 33 Email: gppad@med.lu.se

UNITED KINGDOMLead investigator: Prof. Matthew SnapeDepartment of Paediatrics, University of OxfordRecruiting site: The Women’s Centre, John Radcliffe HospitalOxford, OX3 9DUPhone: +44-(0)-1865-572258Email: INGR1D@wrh.ox.ac.uk

WHO ARE WE

The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) was initiated in 2015. It is an association of several renowned European research institutions providing an international infrastructure that enables type 1 dia-betes primary prevention trials.

OUR VISION

Our long-term vision is to stop the trend of an increasing incidence of childhood type 1 diabetes. There must be global action built around a plat-form that coordinates controlled pre-vention trials. Our vision requires the participation and engagement of clini-cians, scientists, government, layper-sons, and the public at large to pre-vent a lifelong disease that affects 4 in every 1000 children.

WHAT WE DO

Our effort is focused on prevention of the autoimmunity that precedes and destroys the insulin-producing beta cells in the pancreas, eventually leading to type 1 diabetes. Any inter-

vention aiming to prevent type 1 dia-betes has to start in infancy or earlier to avert the autoimmunity that often presents at 9 to 24 months of age. We facilitate this by establishing screening programs for the early detection of an increased genetic risk of type 1 diabe-tes in newborns, such as the Freder1k study in Germany (Bavaria, Lower Sax-ony and Saxony) and Belgium, the AS-TR1D study in Sweden (Skane region), the INGR1D study in the UK (Oxford region) and the newborn screening in Poland (Voivodship Mazowieckie). We will test more than 300,000 babies in the coming years.

The screening program includes a genetic risk score that can identify ne-wborns whose risk of developing the early signs of type 1 diabetes is 1 in 10.

PREVENTION INITIATIVE: POInT

If an increased genetic risk for type 1 diabetes is identified, we inform pa-rents their child can take part in the POInT (Primary Oral Insulin Trial) trial. The trial is testing whether daily admi-nistration of oral insulin can prevent the autoimmunity that leads to type 1 diabetes.